These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1906711)

  • 41. Enhanced thrombin sensitivity of a factor VIII-heparin cofactor II hybrid.
    Voorberg J; van Stempvoort G; Bos JM; Mertens K; van Mourik JA; Donath MJ
    J Biol Chem; 1996 Aug; 271(35):20985-8. PubMed ID: 8702860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of thrombin on human factor VIII. Cleavage of the factor VIII procoagulant protein during activation.
    Hoyer LW; Trabold NC
    J Lab Clin Med; 1981 Jan; 97(1):50-64. PubMed ID: 6778941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant clotting factor VIII concentrates: Heterogeneity and high-purity evaluation.
    D'Amici GM; Timperio AM; Gevi F; Grazzini G; Zolla L
    Electrophoresis; 2010 Aug; 31(16):2730-9. PubMed ID: 20737444
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural and functional characterization of B-domain deleted recombinant factor VIII.
    Sandberg H; Almstedt A; Brandt J; Castro VM; Gray E; Holmquist L; Lewin M; Oswaldsson U; Mikaelsson M; Jankowski MA; Bond M; Scoble HA
    Semin Hematol; 2001 Apr; 38(2 Suppl 4):4-12. PubMed ID: 11449330
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII.
    Pittman DD; Wang JH; Kaufman RJ
    Biochemistry; 1992 Apr; 31(13):3315-25. PubMed ID: 1554716
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis of biologically active deletion mutants of human factor VIII:C.
    Langner KD; Bird RE; McCandliss R; Huber B; Amann E; Zettlmeissl G; Küpper HA
    Behring Inst Mitt; 1988 Apr; (82):16-25. PubMed ID: 3136764
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human factor VIII: purification from commercial factor VIII concentrate, characterization, identification and radiolabeling.
    Hamer RJ; Koedam JA; Beeser-Visser NH; Sixma JJ
    Biochim Biophys Acta; 1986 Oct; 873(3):356-66. PubMed ID: 3092864
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of the B domain for factor VIII and factor V expression and function.
    Pittman DD; Marquette KA; Kaufman RJ
    Blood; 1994 Dec; 84(12):4214-25. PubMed ID: 7994036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proteolysis of blood coagulation factor VIII by the factor VIIa-tissue factor complex: generation of an inactive factor VIII cofactor.
    Warren DL; Morrissey JH; Neuenschwander PF
    Biochemistry; 1999 May; 38(20):6529-36. PubMed ID: 10350471
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma-derived clotting factor VIII: heterogeneity evaluation in the quest for potential inhibitory-antibody stimulating factors.
    D'Amici GM; Blasi B; D'Alessandro A; Vaglio S; Zolla L
    Electrophoresis; 2011 Nov; 32(21):2941-50. PubMed ID: 21997645
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII).
    Pittman DD; Kaufman RJ
    Proc Natl Acad Sci U S A; 1988 Apr; 85(8):2429-33. PubMed ID: 3128786
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Purification and characterization of a highly purified human factor VIII consisting of a single type of polypeptide chain.
    Fay PJ; Chavin SI; Schroeder D; Young FE; Marder VJ
    Proc Natl Acad Sci U S A; 1982 Dec; 79(23):7200-204. PubMed ID: 6818542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human factor VIII from heparinized plasma. Purification and characterization of a single-chain form.
    Ganz PR; Tackaberry ES; Palmer DS; Rock G
    Eur J Biochem; 1988 Jan; 170(3):521-8. PubMed ID: 3123224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.
    Brinkhous KM; Sandberg H; Garris JB; Mattsson C; Palm M; Griggs T; Read MS
    Proc Natl Acad Sci U S A; 1985 Dec; 82(24):8752-6. PubMed ID: 3936044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Copper-atom identification in the active and inactive forms of plasma-derived FVIII and recombinant FVIII-delta II.
    Bihoreau N; Pin S; de Kersabiec AM; Vidot F; Fontaine-Aupart MP
    Eur J Biochem; 1994 May; 222(1):41-8. PubMed ID: 8200351
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells.
    Pittman DD; Tomkinson KN; Kaufman RJ
    J Biol Chem; 1994 Jun; 269(25):17329-37. PubMed ID: 8006042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII.
    Brinkhous K; Sandberg H; Widlund L; Read M; Nichols T; Sigman J; Oswaldsson U; Schaub RG; Mikaelsson M
    Semin Thromb Hemost; 2002 Jun; 28(3):269-72. PubMed ID: 12098087
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thrombin proteolysis of purified factor viii procoagulant protein: correlation of activation with generation of a specific polypeptide.
    Fulcher CA; Roberts JR; Zimmerman TS
    Blood; 1983 Apr; 61(4):807-11. PubMed ID: 6403080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.
    Pahl S; Pavlova A; Driesen J; Müller J; Pötzsch B; Oldenburg J
    Haemophilia; 2013 May; 19(3):392-8. PubMed ID: 23252674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.